Free shipping on all orders over $ 500
About 30 results found for searched term "Raf" (0.009 seconds)
| Cat.No. | Name | Information |
|---|---|---|
| M1669 | Regorafenib | Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
| M1714 | GDC-0879 | GDC-0879 is a potent and selective B-Raf kinase inhibitor with an EC50 of 0.75 µM. |
| M1761 | Vemurafenib (PLX4032) | Vemurafenib (PLX4032) is the first and effective selective inhibitor of B-Raf, which can inhibit RAFV600E and C-RAF-1 activity with IC50 of 31 nM and 48 nM, respectively. Vemurafenib induces autophagy. |
| M1774 | PLX-4720 | PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. |
| M1783 | SB590885 | SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively. |
| M1818 | ZM 336372 | ZM 336372 is a potent, selective ATP-competitive inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf). |
| M1827 | Sorafenib Tosylate | Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. |
| M1855 | Dabrafenib Mesylate | Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. |
| M1863 | RAF265 | RAF265 is a novel, orally bioavailable dual inhibitor of RAF kinase and VEGFR2. |
| M1934 | Tacrolimus (FK506) | Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. *The compound is unstable in solutions, freshly prepared is recommended |
| M1988 | Dabrafenib | Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. |
| M25447 | PR-104 | PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy. |
| M2045 | CEP-32496 | CEP-32496 is a potent orally active BRAF inhibitor with IC50 of 14 nM. |
| M2090 | MLN2480 | MLN2480 (BIIB-024) is an oral, selective pan-Raf kinase inhibitor. |
| M2235 | TAK-632 | TAK-632 is a potent and selective pan-RAF inhibitor. |
| M2319 | AZ628 | AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively. |
| M2608 | Kobe0065 | Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD, exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. |
| M2743 | GW2580 | GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc. |
| M2744 | GW441756 | GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2. |
| M2745 | GW5074 | GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. |
| M2813 | LGX818 | LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. |
| M2927 | PF-04880594 | PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38. |
| M3026 | Sorafenib (BAY 43-9006) | Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
| M3196 | CCT239065 | CCT239065 is a novel and selective BRAFV600E and LCK inhibitor with IC50 of 13 nM and 6 nM, respectively. |
| M3898 | YK-4-279 | YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts. |
| M4551 | Trigonelline-Hydrochloride | As an NRF2 inhibitor, fenuelline blocks the expression of NRF2 target genes associated with heme and iron metabolism, synergistic with Erastin and sorafenib to promote iron death in hepatocellular carcinoma cells. |
| M4644 | Dryocrassin-ABBA | Dryocrassin ABBA (Dryocrassin) is a natural product of flavonoids extracted from Sophora flavescens, with antiviral and antibacterial activities. Dryocrassin ABBA has antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA could inhibit coagulase activity of STaphylococcus aureus vWbp. Dryocrassin ABBA can inhibit the immune stimulation of dendritic cells and prolong the survival rate of allografts. |
| M4869 | BAY 87-2243 | BAY87-2243 is a potent inhibitor of selective hypoxia-inducible facin-1 (HIF-1). Bay87-2243 induces iron death and necrosis in BRAFV600E melanoma cells by inhibiting the mitochondrial respiratory chain, resulting in ROS accumulation, lipid peroxidation, and GSH deletion. |
| M5005 | Regorafenib Monohydrate | Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
| M5059 | Furafylline | Furafylline was a potent, non-competitive inhibitor of high affinity phenacetin O-deethylase activity of microsomal fractions of human liver, a reaction catalysed by P450IA2, with an IC50 value of 0.07 microM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
